Cite
HARVARD Citation
Biziotis, O. et al. (n.d.). 40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy. Radiotherapy and oncology. pp. S20-. [Online].